viewKazia Therapeutics Ltd

Kazia Therapeutics substantial holder increases position

Kazia recently completed recruitment for the phase II clinical trial testing its development drug paxalisib on aggressive brain cancer.

Kazia Therapeutics Ltd - Kazia Therapeutics substantial holder grows position
Data from the study will be revealed at an upcoming cancer conference on 24-29 April 2020

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder The Bank of New York Mellon Corporation has increased its shareholding to 28.54%.

A number of purchases throughout the month of March 2020 has grown the holding from 19.79 million shares to 20.59 million shares.

Trial recruitment recently completed

Kazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain cancer.

The company recently completed recruitment for the phase II clinical trial in newly-diagnosed glioblastoma (aggressive brain cancer).

30 patients were recruited at six sites in the US and the final patient commenced dosing on 27 February 2020.

Kazia has been accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego, CA on 24-29 April 2020.

Quick facts: Kazia Therapeutics Ltd

Price: 0.465 AUD

Market: ASX
Market Cap: $33.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 25/11/19

2 min read